Double-blind comparison of buspirone and clorazepate in anxious outpatients

Jay B. Cohn, Charles L. Bowden, Johnnie G. Fisher, J. Jerry Rodos

Research output: Contribution to journalArticlepeer-review

56 Scopus citations


Buspirone, a new nonbenzodiazepine anxiolytic agent, was compared with clorazepate in a double-blind, multicenter trial conducted with 336 outpatients who had moderate to severe anxiety. The two treatments were equally effective for relief of symptoms, including anxiety with associated depression. Although both agents were generally well tolerated, the profile of side effects was dissimilar. Drowsiness and depression occurred significantly (p <0.055) more frequently with clorazepate, whereas nausea and headache occurred significantly (p <0.055) more frequently with buspirone. Clorazepate-treated patients were significantly (p <0.055) more likely to have had an adverse experience that was considered drug related or that interfered with the therapeutic effect. In this study, buspirone was shown to be an effective antianxiety agent, causing significantly less sedation than clorazepate.

Original languageEnglish (US)
Pages (from-to)10-16
Number of pages7
JournalThe American Journal of Medicine
Issue number3 SUPPL. 2
StatePublished - Mar 31 1986

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Double-blind comparison of buspirone and clorazepate in anxious outpatients'. Together they form a unique fingerprint.

Cite this